Enliven Therapeutics, Inc.
ELVN
$36.33
$0.220.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -98.78M | -103.69M | -97.21M | -100.22M | -94.83M |
| Total Depreciation and Amortization | 203.00K | 263.00K | 297.00K | 315.00K | 312.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 35.17M | 34.25M | 28.09M | 27.03M | 22.96M |
| Change in Net Operating Assets | -2.06M | -1.12M | -2.85M | 2.30M | -2.40M |
| Cash from Operations | -65.47M | -70.30M | -71.67M | -70.58M | -73.96M |
| Capital Expenditure | -138.00K | -158.00K | -158.00K | -181.00K | -44.00K |
| Sale of Property, Plant, and Equipment | 213.00K | 213.00K | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -132.82M | -173.90M | -185.34M | -166.43M | -16.64M |
| Cash from Investing | -132.74M | -173.84M | -185.49M | -166.61M | -16.69M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 229.15M | 219.33M | 258.58M | 259.70M | 43.13M |
| Repurchase of Common Stock | -249.00K | -249.00K | -249.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -217.00K | -217.00K | -119.00K | -- | -- |
| Cash from Financing | 228.69M | 218.87M | 258.22M | 259.70M | 43.13M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 30.48M | -25.28M | 1.06M | 22.51M | -47.51M |